Atrofias musculares espinales no asociadas a SMN1

Darras, 2015, Spinal muscular atrophies, Pediatr Clin North Am., 62, 743, 10.1016/j.pcl.2015.03.010 Darras, 2011, Non-5q spinal muscular atrophies: the alphanumeric soup thickens, Neurology. United States, 77, 312, 10.1212/WNL.0b013e3182267bd8 Garg, 2016, Differentiating lower motor neuron syndromes, J Neurol Neurosurg Psychiatry [Internet]. Teoh, 2017, Inherited Paediatric Motor Neuron Disorders: Beyond Spinal Muscular Atrophy, Neural Plasticity, 2017, 10.1155/2017/6509493 D’Amico, 2011, Spinal muscular atrophy, Orphanet J Rare Dis., 6, 71, 10.1186/1750-1172-6-71 Mercuri, 2012, Childhood spinal muscular atrophy: Controversies and challenges, The Lancet Neurology., 11, 443, 10.1016/S1474-4422(12)70061-3 Verhaart, 2017, Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review, Orphanet J Rare Dis [Internet]., 12, 124, 10.1186/s13023-017-0671-8 Wirth, 2000, An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA), Human Mutation, 15, 228, 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9 Echaniz-Laguna, 2015, The shifting paradigm of Charcot-Marie-Tooth disease, Rev Neurol (Paris), 171, 498, 10.1016/j.neurol.2014.12.003 Efthymiou, 2016, Next-generation sequencing in neuromuscular diseases, Current Opinion in Neurology., 29, 527, 10.1097/WCO.0000000000000374 Dowling, 2017, Treating pediatric neuromuscular disorders: The future is now, Am J Med Genet Part A [Internet]., 1 Bharucha-Goebel D, Kaufmann P. Treatment Advances in Spinal Muscular Atrophy. Vol. 17, Current Neurology and Neuroscience Reports. 2017. Parente, 2018, Advances in spinal muscular atrophy therapeutics, Ther Adv Neurol Disord [Internet]., 11 Rossor, 2012, The distal hereditary motor neuropathies, J Neurol Neurosurg Psychiatry [Internet]., 6, 10.1136/jnnp-2011-300952 Arnold, 2015, Spinal muscular atrophy: Diagnosis and management in a new therapeutic era, Muscle Nerve [Internet]., 51, 157, 10.1002/mus.24497 Buchthal, 1970, Electromyography and muscle biopsy in infantile spinal muscular atrophy, Brain., 93, 15, 10.1093/brain/93.1.15 Grohmann, 2001, Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1, Nat Genet., 29, 75, 10.1038/ng703 Grohmann, 2003, Infantile Spinal Muscular Atrophy with Respiratory Distress Type 1 (SMARD1), Ann Neurol., 54, 719, 10.1002/ana.10755 Jędrzejowska, 2014, Severe phenotypes of SMARD1 associated with novel mutations of the IGHMBP2 gene and nuclear degeneration of muscle and Schwann cells, Eur J Paediatr Neurol., 18, 183, 10.1016/j.ejpn.2013.11.006 Vanoli, 2015, Clinical and molecular features and therapeutic perspectives of spinal muscular atrophy with respiratory distress type 1, J Cell Mol Med., 19, 2058, 10.1111/jcmm.12606 Wagner, 2015, Autosomal recessive axonal polyneuropathy in a sibling pair due to a novel homozygous mutation in IGHMBP2, Neuromuscul Disord., 25, 794, 10.1016/j.nmd.2015.07.017 Luan, 2016, Infantile spinal muscular atrophy with respiratory distress type I presenting without respiratory involvement: Novel mutations and review of the literature, Brain Dev., 38, 685, 10.1016/j.braindev.2016.02.001 Cottenie, 2014, Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2, Am J Hum Genet., 95, 590, 10.1016/j.ajhg.2014.10.002 Pitt, 2003, Severe infantile neuropathy with diaphragmatic weakness and its relationship to SMARD1, Brain., 126, 2682, 10.1093/brain/awg278 Nizzardo, 2015, Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model, Sci Adv [Internet]., 1, e1500078, 10.1126/sciadv.1500078 Shababi, 2016, Rescue of a Mouse Model of Spinal Muscular Atrophy with Respiratory Distress type 1 (SMARD1) by AAV9-IGHMBP2 is Dose Dependent, Mol Ther., 1 Evangelista, 2015, Phenotypic variability of TRPV4 related neuropathies, Neuromuscul Disord., 25, 516, 10.1016/j.nmd.2015.03.007 McEntagart, 2012, TRPV4 axonal neuropathy spectrum disorder, J Clin Neurosci [Internet]., 19, 927, 10.1016/j.jocn.2011.12.003 Nilius, 2013, The puzzle of TRPV4 channelopathies, EMBO Rep [Internet]., 14, 152, 10.1038/embor.2012.219 Dai, 2010, TRPV4-pathy, a novel channelopathy affecting diverse systems, Journal of Human Genetics., 55, 400, 10.1038/jhg.2010.37 Andreucci, 2011, TRPV4 related skeletal dysplasias: A phenotypic spectrum highlighted byclinical, radiographic, and molecular studies in 21 new families, Orphanet J Rare Dis., 6, 10.1186/1750-1172-6-37 Oonk, 2014, Intrafamilial variable hearing loss in TRPV4 induced spinal muscular atrophy, Ann Otol Rhinol Laryngol., 123, 859, 10.1177/0003489414539130 Echaniz-Laguna, 2014, Phenotypic spectrum and incidence of TRPV4 mutations in patients with inherited axonal neuropathy, Neurology., 82, 1919, 10.1212/WNL.0000000000000450 Auer-Grumbach, 2010, Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C, Nat Genet., 42, 160, 10.1038/ng.508 Fiorillo, 2012, TRPV4 mutations in children with congenital distal spinal muscular atrophy, Neurogenetics., 13, 195, 10.1007/s10048-012-0328-7 Biasini, 2016, TRPV4 related scapuloperoneal spinal muscular atrophy: Report of an Italian family and review of the literature, Neuromuscul Disord., 26, 312, 10.1016/j.nmd.2016.02.010 Bosch, 2012, The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: Natural history, genetics, treatment and future perspectives, Orphanet Journal of Rare Diseases., 7, 10.1186/1750-1172-7-83 Bashford, 2017, Remarkable motor recovery after riboflavin therapy in adult-onset Brown–Vialetto–Van Laere syndrome, Pr Neurol [Internet]., 17, 53, 10.1136/practneurol-2016-001488 Jaeger, 2016, Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience, J Inherit Metab Dis., 39, 559, 10.1007/s10545-016-9924-2 Rizzo, 2017, Genome-wide RNA-seq of iPSC-derived motor neurons indicates selective cytoskeletal perturbation in Brown-Vialetto disease that is partially rescued by riboflavin, Sci Rep., 7, 46271, 10.1038/srep46271 Scoto, 2015, Novel mutations expand the clinical spectrum of DYNC1H1-associated spinal muscular atrophy, Neurology., 84, 668, 10.1212/WNL.0000000000001269 Oates, 2013, Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic paraplegia, Am J Hum Genet., 92, 965, 10.1016/j.ajhg.2013.04.018 Strickland, 2015, Mutation screen reveals novel variants and expands the phenotypes associated with DYNC1H1, J Neurol., 262, 2124, 10.1007/s00415-015-7727-2 Rudnik-Schöneborn, 2014, Pontocerebellar hypoplasia, Am J Med Genet Part C Semin Med Genet., 166, 173, 10.1002/ajmg.c.31403 Namavar, 2011, Classification, diagnosis and potential mechanisms in Pontocerebellar Hypoplasia, Orphanet Journal of Rare Diseases., 6, 10.1186/1750-1172-6-50 La Spada a, 1991, Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy, Nature [Internet], 352, 77, 10.1038/352077a0 Manzano, 2018, Beyond motor neurons: expanding the clinical spectrum in Kennedy's disease, J Neurol Neurosurg Psychiatry [Internet]., 10.1136/jnnp-2017-316961 Pennuto, 2017, From gene to therapy in spinal and bulbar muscular atrophy: Are we there yet?, Mol Cell Endocrinol [Internet] Volk, 2017, The rapid evolution of molecular genetic diagnostics in neuromuscular diseases, Current Opinion in Neurology, 30, 523, 10.1097/WCO.0000000000000478 Xue, 2015, Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing, Genet Med [Internet], 17, 444, 10.1038/gim.2014.122